designation

SYDNEY, Australia and NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- EnGeneIC, an innovative biopharmaceutical company leading the field of armed antibody therapeutics for oncology, has achieved a significant milestone with the granting of…

WALTHAM, Mass., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet…

Delhi, July 26, 2023 (GLOBE NEWSWIRE) -- US Orphan Drugs Market, Drugs Sales, Price, Dosage & Clinical Trials Insight 2028 Report Highlights: US Orphan Drugs Market Opportunity: > USD 150 Billion By 2028Orphan Drugs Dosage, Price…

Reinventing Vitamin A for neonatal and pediatric unmet medical needsBronchopulmonary Dysplasia (BPD) is most frequent serious complication of preterm birth – US preterm births highest in 15 yearsAdvent plans FDA PDUFA Meeting late-2023 to…

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 20, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the Center for Drug Evaluation of China’s National Medical…

SAN DIEGO, July 19, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Ambrx’s proprietary…

CAMBRIDGE, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today…

HOUSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological…

– Zeno se voit accorder une BTD pour le traitement du cancer du poumon non à petites cellules NRG1+ UTRECHT, Pays-Bas et CAMBRIDGE, Mass., 06 juill. 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), une société d'oncologie au stade…

NEW YORK and LONDON, July 06, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the European…